Body weight remained stable, and blood glucose levels showed a trend of decrease but not significant in dapagliflozin-treated groups ( Figure S4E,F ). 3.
← all excerpts
SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence.
1
—
—